True Gold R&D Services Agreement—Amendment IR&d Services Agreement • December 28th, 2022 • Empatan Public LTD Co • Misc industrial & commercial machinery & equipment
Contract Type FiledDecember 28th, 2022 Company IndustryThis Amendment dated May 26, 2022 (“Amendment”), is to that certain agreement entered into on 16 November 2020 (“Agreement”), by and between Security Matters, Ltd an Israeli corporation PC #515125771 c/- K&L Gates, L25, 525 Collins Street, Melbourne, Victoria 3000 (“SMX”) and True Gold Consortium Pty Ltd ACN 641 483 374 of Suite 124, 341B Cambridge Street, Wembley Western Australia 6014 (“TrueGold”). Each a “Party” and, together, the “Parties”.
AMENDMENT NUMBER TWO TO THE R&D SERVICES AGREEMENTR&d Services Agreement • November 9th, 2018 • LIGHTBRIDGE Corp • Services-management consulting services
Contract Type FiledNovember 9th, 2018 Company IndustryThis Amendment Number Two (“Amendment Two”) amends the 14 November 2017 R&D Services Agreement (“RDSA” or “Agreement”), as previously amended by Amendment Number One dated June 20, 2018, between Framatome SAS (formerly known as “AREVA NP SAS”, and hereinafter referred to as “Framatome”), Lightbridge Corporation (“Lightbridge”), and Enfission, LLC (“Enfission”) (each of Framatome, Lightbridge and Enfission a “Party”, and collectively, the “Parties”), and shall be deemed effective as of June 20, 2018.
TOXYS R&D SERVICES AGREEMENTR&d Services Agreement • March 28th, 2022 • New York
Contract Type FiledMarch 28th, 2022 JurisdictionThis R&D Services Agreement (the “Agreement”), is made by and between TOXYS, Inc., a Delaware corporation (“TOXYS”) and [XXXX], a [STATE] [corporation/company with limited liability], (“Customer” (each individually referred to herein as a “Party” and collectively as the “Parties”), as of [ ] (the “Effective Date”).
ContractR&d Services Agreement • November 9th, 2018 • LIGHTBRIDGE Corp • Services-management consulting services
Contract Type FiledNovember 9th, 2018 Company Industry[*****] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.